VivoSeq
Oncology

Bone Metastases

0

Pipeline Programs↗

3

Active Trials↗

4

Companies Involved↗

Bone Metastases is an early-stage landscape with 0 programs across 4 companies. The most active players are Suzhou Suncadia Biopharmaceuticals Co., Ltd., GSK, Central European Cooperative Oncology Group.

Intelligence

Pipeline Metrics

Competitive Density

14/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

75/100

Attrition Rate

15/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Suzhou Suncadia Biopharmaceuticals Co., Ltd. logo

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

0 programs

PreclinicalGSK logo

GSK

0 programs

PreclinicalC

Central European Cooperative Oncology Group

0 programs

PreclinicalF

Five Eleven Pharma, Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

20

clinical trials

Completed9 · 45%
Unknown status5 · 25%
Recruiting3 · 15%
Terminated2 · 10%
Withdrawn1 · 5%

Clinical Trials

Trial Activity

20 trials

Palliative Dose Escalated Radiation for Painful Non-Spine Bone Metastases and Painful Non-Bone Metas
Recruiting·RRutgers, The State University of New Jersey·Phase 2·NCT05419518·124 enrolled
Early Radiotherapy Versus Observation for High-risk Asymptomatic or Minimally Symptomatic Bone Metastases
Recruiting·CCancer Research Antwerp·N/A·NCT07146074·120 enrolled
A Trial of SHR-2017 Injection in Patients With Bone Metastases From Solid Tumors
Recruiting·Suzhou Suncadia Biopharmaceuticals Co., Ltd. logoSuzhou Suncadia Biopharmaceuticals Co., Ltd.·Phase 2·NCT07028268·210 enrolled
4-weekly Versus 12-weekly Administration of Bone-targeted Agents in Patients With Bone Metastases
Completed·OOttawa Hospital Research Institute·Phase 4·NCT02721433·263 enrolled
A Study to Compare Denosumab With Zoledronic Acid in Subjects With Bone Metastases From Solid Tumors
Completed·GSK logoGSK·Phase 3·NCT01920568·487 enrolled
Dexamethasone for Pain Flare After Radiotherapy of Painful Bone metastasesZonMW 11510009
Completed·UUMC Utrecht·Phase 3·NCT01669499·411 enrolled
Diagnostic Performance and Safety of 18F-NaF-PET/CT in Bone Metastases Compared With 99mTc⁃MDP-BS±SPECT
Completed·HHTA Co., Ltd.·Phase 3·NCT05614518·280 enrolled
S0916, MLN1202 in Treating Patients With Bone Metastases
Completed·SWOG Cancer Research Network·Phase 2·NCT01015560·44 enrolled
Dexamethasone vs Placebo in the Prophylaxis of Radiation-Induced Pain Flare Following Palliative Radiotherapy for Bone Metastases
Completed·NNCIC Clinical Trials Group·Phase 3·NCT01248585·298 enrolled
PK/PD Study of SHR-2017 Injection in Patients With Bone Metastases
Completed·Suzhou Suncadia Biopharmaceuticals Co., Ltd. logoSuzhou Suncadia Biopharmaceuticals Co., Ltd.·Phase 1·NCT06380881·25 enrolled
Preliminary Evaluation of Uptake in Bone Metastases and Biodistribution of [68Ga]P15-041
Completed·FFive Eleven Pharma, Inc.·Phase 1·NCT02826382·14 enrolled
Evaluation of an Accelerated Body-whole Bone CT Procedure With the CZT(Cadmium-Zinc-Telluride) "VERITON-CT ™" Camera: a Comparison With the Conventional Full-body 2D Recording Procedure With or Without Complementary Tomoscintigraphy.
Completed·CCentral Hospital, Nancy, France·Preclinical·NCT04157166·146 enrolled
3 Tesla Magnetic Resonance Guided High Intensity Focused Ultrasound in the Treatment of Pain From Bone Metastases of Solid Tumors
Terminated·IIstituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS·N/A·NCT02718404·12 enrolled
ZOMETA® (Zoledronic Acid) for Prevention of Bone Metastases
Terminated·CCentral European Cooperative Oncology Group·Phase 3·NCT00294437·376 enrolled
MRI Guided High Intensity Focused Ultrasound (HIFU) and ThermoDox for Palliation of Painful Bone Metastases
Withdrawn·IImunon·Phase 2·NCT01640847
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)